TSXV:CZO

Stock Analysis Report

Executive Summary

Ceapro Inc., a biotechnology company, engages in developing and commercializing active ingredients in the United States, Canada, Germany, China, and internationally.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.

Share Price & News

How has Ceapro's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CZO has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.9%

CZO

0.3%

CA Chemicals

0.6%

CA Market


1 Year Return

-27.2%

CZO

-11.0%

CA Chemicals

7.1%

CA Market

Return vs Industry: CZO underperformed the Canadian Chemicals industry which returned -11% over the past year.

Return vs Market: CZO underperformed the Canadian Market which returned 7.1% over the past year.


Shareholder returns

CZOIndustryMarket
7 Day-2.9%0.3%0.6%
30 Day-6.9%2.3%3.2%
90 Day-16.3%-0.5%4.3%
1 Year-27.2%-27.2%-7.9%-11.0%10.7%7.1%
3 Year-77.4%-77.4%1.4%-4.4%18.4%7.8%
5 Year-20.2%-20.2%-14.8%-23.8%26.8%8.2%

Price Volatility Vs. Market

How volatile is Ceapro's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ceapro undervalued compared to its fair value and its price relative to the market?

1.17x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CZO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CZO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CZO is unprofitable, so we can't compare its PE Ratio to the Chemicals industry average.

PE vs Market: CZO is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CZO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CZO is good value based on its PB Ratio (1.2x) compared to the CA Chemicals industry average (1.2x).


Next Steps

Future Growth

How is Ceapro forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.8%

Forecasted Materials industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ceapro has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Ceapro performed over the past 5 years?

-36.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CZO has large one-off items impacting its financial results.

Growing Profit Margin: CZO's current net profit margins (-8.2%) are higher than last year (-15.6%).


Past Earnings Growth Analysis

Earnings Trend: CZO is unprofitable, and losses have increased over the past 5 years at a rate of -36.6% per year.

Accelerating Growth: Unable to compare CZO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CZO is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-20.5%).


Return on Equity

High ROE: CZO has a negative Return on Equity (-4.73%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Ceapro's financial position?


Financial Position Analysis

Short Term Liabilities: CZO's short term assets (CA$5.7M) exceeds its short term liabilities (CA$1.6M)

Long Term Liabilities: CZO's short term assets (5.7M) exceeds its long term liabilities (3.6M)


Debt to Equity History and Analysis

Debt Level: CZO's debt to equity ratio (1.9%) is considered satisfactory

Reducing Debt: CZO's debt to equity ratio has reduced from 318.2% to 1.9% over the past 5 years.

Debt Coverage: CZO's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if CZO's interest payments on its debt are well covered by EBIT.


Balance Sheet

Inventory Level: CZO has a high level of physical assets or inventory.

Debt Coverage by Assets: CZO's debt is covered by short term assets (assets are 14x debt).


Next Steps

Dividend

What is Ceapro's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%5.7%industryaverage2.2%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CZO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CZO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CZO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CZO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CZO's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Ceapro's salary, the management and board of directors tenure and is there insider trading?

8.6yrs

Average board tenure


CEO

Gilles Gagnon (65yo)

7.3yrs

Tenure

CA$555,000

Compensation

Mr. Gilles R. Gagnon, M.Sc., MBA, ICD.D, serves as the President of Spectrum Pharma Canada Inc. (Spectrum Canada). Mr. Gagnon has been Chief Executive Officer and President of Ceapro Inc. since July 1, 201 ...


CEO Compensation Analysis

Compensation vs Market: Gilles's total compensation ($USD419.58K) is above average for companies of similar size in the Canadian market ($USD136.08K).

Compensation vs Earnings: Gilles's compensation has been consistent with company performance over the past year.


Board Age and Tenure

8.6yrs

Average Tenure

Experienced Board: CZO's board of directors are considered experienced (8.6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Gilles Gagnon (65yo)

    CEO, President & Director

    • Tenure: 7.3yrs
    • Compensation: CA$555.00k
  • Stacy Prefontaine

    CFO & Corporate Secretary

    • Tenure: 4.5yrs
    • Compensation: CA$213.12k
  • Marc Morisset

    Director of Sales & Marketing

    • Tenure: 0yrs
  • Bernhard Seifried

    Director of Engineering Research & Technologies

    • Tenure: 0yrs

Board Members

  • Gilles Gagnon (65yo)

    CEO, President & Director

    • Tenure: 7.3yrs
    • Compensation: CA$555.00k
  • Will Li (56yo)

    Independent Director

    • Tenure: 5yrs
    • Compensation: CA$32.40k
  • John Zupancic

    Independent Director

    • Tenure: 21.8yrs
    • Compensation: CA$30.00k
  • Don Oborowsky

    Independent Director

    • Tenure: 20.8yrs
    • Compensation: CA$25.00k
  • Glenn Rourke

    Independent Chairman of the Board

    • Tenure: 5.1yrs
    • Compensation: CA$35.00k
  • Ulrich Kosciessa

    Independent Director

    • Tenure: 4.6yrs
    • Compensation: CA$38.25k

Company Information

Ceapro Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ceapro Inc.
  • Ticker: CZO
  • Exchange: TSXV
  • Founded: 1997
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: CA$25.908m
  • Shares outstanding: 77.34m
  • Website: https://www.ceapro.com

Location

  • Ceapro Inc.
  • 7824 – 51 Avenue NW
  • Edmonton
  • Alberta
  • T6E 6W2
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CZOTSXV (TSX Venture Exchange)YesClass A Voting Common SharesCACADSep 1988
CRPO.FOTCPK (Pink Sheets LLC)YesClass A Voting Common SharesUSUSDSep 1988
385DB (Deutsche Boerse AG)YesClass A Voting Common SharesDEEURSep 1988

Biography

Ceapro Inc., a biotechnology company, engages in developing and commercializing active ingredients in the United States, Canada, Germany, China, and internationally. The company is involved in the developm ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/16 23:33
End of Day Share Price2019/11/15 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.